Human medicines European public assessment report (EPAR): Apealea, paclitaxel, Ovarian Neoplasms, Date of authorisation: 20/11/2018, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Apealea, paclitaxel, Ovarian Neoplasms, Date of authorisation: 20/11/2018, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Januvia, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 20/03/2007, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Januvia, sitagliptin, Diabetes Mellitus, Type 2, Date of authorisation: 20/03/2007, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib, Alopecia Areata, Date of authorisation: 15/09/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Litfulo, ritlecitinib, Alopecia Areata, Date of authorisation: 15/09/2023, Status: Authorised

Joint EMA-ECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA, Online, 14:30 – 15:00 Amsterdam time (CEST), from 21/09/2023 to 21/09/2023

Joint EMA-ECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA, Online, 14:30 – 15:00 Amsterdam time (CEST), from 21/09/2023 to 21/09/2023

Human medicines European public assessment report (EPAR): Lumeblue (previously known as Methylthioninium chloride Cosmo), methylthioninium chloride, Colorectal Neoplasms;Colonoscopy, Date of authorisation: 19/08/2020, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Lumeblue (previously known as Methylthioninium chloride Cosmo), methylthioninium chloride, Colorectal Neoplasms;Colonoscopy, Date of authorisation: 19/08/2020, Revision: 3, Status: Authorised

Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Epilepsy;Anxiety Disorders;Neuralgia, Date of authorisation: 05/07/2004, Revision: 61, Status: Authorised

Human medicines European public assessment report (EPAR): Lyrica, pregabalin, Epilepsy;Anxiety Disorders;Neuralgia, Date of authorisation: 05/07/2004, Revision: 61, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): Evkeeza,Evinacumab, decision type: , therapeutic area: , PIP number: P/0394/2022

Opinion/decision on a Paediatric investigation plan (PIP): Evkeeza,Evinacumab, decision type: , therapeutic area: , PIP number: P/0394/2022

Human medicines European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau), chenodeoxycholic acid, Xanthomatosis, Cerebrotendinous;Metabolism, Inborn Errors, Date of authorisation: 10/04

Human medicines European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau), chenodeoxycholic acid, Xanthomatosis, Cerebrotendinous;Metabolism, Inborn Errors, Date of authorisation: 10/04/2017, Revision: 6, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.